Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Circulating tumor DNA and late recurrence in high-risk, hormone receptor-positive, HER2-negative breast cancer: An updated analysis of the CHiRP study.

With longer follow-up, all 8/8 patients with ctDNA detected at any timepoint developed distant recurrence (median lead time 1.39 years, range 0.01-4.24). A negative test had a negative predictive value for remaining recurrence-free of 100% at more than 1 year (0/196), 98.4% at more than 2 years (3 events among 185 samples), and 96.6% at more than 3 years (5/147).

ASCO Annual Meeting 2025PubMed 35658506